Top Markets
#1 Black Phoenix Black Phoenix +355.18%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.04%
#4 Akedo Akedo +53.98%
#5 Acurast Acurast +32.15%
#6 BasedHype BasedHype +28.07%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +18.15%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.84%
#10 HOME HOME +14.70%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Rank in Stocks #40868
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Share Price
$0.02765
Last synced: 2024-12-23
Market Cap
$69.04K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Histogen Inc. (HSTO)

Category

Healthcare
P/E ratio for Histogen Inc. (HSTO)
P/E ratio as of August 2026 TTM: -0.01
According to Histogen Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.01. At the end of 2021 the company had a P/E ratio of -0.08.
P/E ratio history for Histogen Inc. from 2011 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.01 -80.67%
2022 -0.03 -70.37%
2021 -0.08 132.05%
2020 -0.04 -91.21%
2019 -0.42 42.30%
2018 -0.29 -61.58%
2017 -0.76 89.09%
2016 -0.40 -99.10%
2015 -44.41 -54.26%
2014 -97.09 59.73%
2013 -60.78 5,948.63%
2012 -1.00 37.11%
2011 -0.73 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -483,689.66%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -537,068.97%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -332,836.21%
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.